STOCKHOLM, April 27,
2022 /PRNewswire/ -- The below resolutions were
passed at Medicover's annual general meeting (the "AGM") held today
on 27 April 2022. In accordance with
the Act (2022:121) on temporary exceptions to facilitate the
execution of general meetings in companies and other associations,
the AGM was carried out through postal voting without any physical
attendance.
Election of the board of directors and auditor
The AGM resolved, in accordance with the proposal from the
nomination committee, that the number of board members appointed by
the shareholders' meeting shall be ten. Fredrik Stenmo, Peder af Jochnick, Robert af
Jochnick, Arno Bohn, Sonali
Chandmal, Michael Flemming,
Margareta Nordenvall and Fredrik Rågmark were re-elected, whereas
Anne Berner and Azita Shariati were elected, as board members.
Fredrik Stenmo was re-elected as the
chairman of the board. The AGM resolved that the number of auditors
shall be one without deputies and to re-elect BDO Sweden AB as the
company's auditor, with Jörgen Lövgren as auditor in charge, which
is in accordance with the audit committee's recommendation.
Fees to board members and auditor
The AGM resolved that the fees to the board members shall be
paid out in a total amount of EUR
581,350, divided so that the chairman of the board of
directors shall receive EUR 74,000
and the other board members who are not employed by the group shall
receive EUR 53,000 each, the chairman
of the audit committee shall receive EUR
23,000 and each other member of the audit committee who is
not employed by the group shall receive EUR
11,250 each, the chairman of the remuneration committee
shall receive EUR 8,200 and each
other member of the remuneration committee who is not employed by
the group shall receive EUR 8,200
each, as well as EUR 5,100 for the
chairman of the sustainability committee and EUR 5,100 for each other member of the
sustainability committee who is not employed by the group. It was
resolved that the auditor's fees shall be paid as per approved
account.
Adoption of the annual accounts, allocation of the results
and discharge from liability
The AGM resolved to adopt the annual accounts for the company
and the group for 2021. In accordance with the proposal from the
board of directors, the AGM determined that dividend of
EUR 0.12 per share shall be paid for
2021 and record date for dividend is Friday 29 April 2022. Euroclear Sweden AB is expected to
disburse dividend on Friday 6 May
2022. The last day for trading in the company's share
including right to dividend is Wednesday 27
April 2022. Furthermore, the AGM resolved to discharge the
board members and the CEO from liability.
Remuneration report
The AGM approved the remuneration report prepared by the board
of directors.
Instructions to the nomination committee
The AGM adopted the nomination committee's proposed instructions
to the nomination committee.
Guidelines for remuneration to senior executives
The AGM adopted the board of directors' proposed guidelines for
remuneration to senior executives.
Long term performance-based share program
The AGM resolved, in accordance with the proposal from the board
of directors, to adopt a long term performance-based share program
for group management and other key individuals within the Medicover
group, including a maximum of 93 participants. The participants in
the program are required to invest in Medicover by investing in
Class B shares in the company. The participants will, provided that
certain conditions are met, be granted Class B shares free of
charge. Further, the AGM resolved, in accordance with the proposal
from the board of directors, to adopt certain hedging arrangements
in order to secure the delivery of shares to the participants at
the end of the program. The hedging arrangements include an
authorisation for the board of directors to issue a maximum of
1,344,440 Class C shares, of which not more than 58,440 Class C
shares may be issued to secure social charges, an authorisation for
the board of directors to repurchase all issued Class C shares and
a resolution to transfer the repurchased shares, following
reclassification into Class B shares, to the participants in the
program as well as in the market in order to cover the cash flow
effects arising as a result of payments of social charges.
Authorisation for the board of directors to resolve to issue
new shares
The AGM authorised, in accordance with the proposal from the
board of directors, the board of directors to, at one or several
occasions and for the period until the next annual general meeting,
resolve to issue new Class B shares. The purpose is to increase the
financial flexibility of the company and the acting scope of the
board of directors. The authorisation allows the board of directors
to resolve to increase the company's share capital by issue of new
shares at one or several occasions and for the time period until
the end of the next annual general meeting, with or without
deviation from the shareholders' preferential rights and with or
without provisions for contribution in kind, set-off or other
conditions, to the extent that it corresponds to a dilution of not
more than ten per cent of the number of shares outstanding at the
time of the shareholders' meeting's resolution on the proposed
authorisation.
Authorisation for the board of directors to resolve to
repurchase own shares
The AGM authorised, in accordance with the proposal from the
board of directors, the board of directors to resolve upon
repurchases of own shares of class B, on one or several occasions
prior to the annual general meeting 2023. The purpose of the
authorisation is to promote efficient capital usage in the company
and to provide flexibility as regards the company's possibilities
to distribute capital to its shareholders. Repurchase shall maximum
comprise so many shares of class B that the company's holding does
not at any time exceed ten per cent of the total number of shares
in the company. Repurchase may only take place on Nasdaq Stockholm
and only at a price within the price range applicable at any given
time, i.e. the range between the highest purchase price and the
lowest selling price.
The underlying proposals to the above resolutions are published,
and at the latest on 11 May 2022 also
the minutes from the AGM will be published, at
www.medicover.com.
For further information, please contact:
Hanna Bjellquist, Head of
Investor Relations
+46 703 033 272
hanna.bjellquist@medicover.com
Medicover is a leading international healthcare and
diagnostic services company and was founded in 1995. Medicover
operates a large number of ambulatory clinics, hospitals,
specialty-care facilities, laboratories and blood-drawing points
and the largest markets are Poland
and Germany. In 2021, Medicover
had revenue of EUR 1,377 million and
more than 38,000 employees. For more information, go to
www.medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/bulletin-from-annual-general-meeting-in-medicover-ab--publ-,c3554596
The following files are available for download:
https://mb.cision.com/Main/15662/3554596/1570108.pdf
|
Bulletin from AGM
2022
|